Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP1024 | DOI: 10.1530/endoabs.81.EP1024

ECE2022 Eposter Presentations Thyroid (219 abstracts)

TSHR promoter methylation level changes as a prognostic blood-based biomarker in follicular thyroid carcinoma

Mintaute Kazokaite1, Kristina Zukauskaite2, 3, Raimonda Klimaitė1,4, Aistė Kondrotienė1,4, Dalia Daukšienė1, Birute Zilaitiene1, 4, Rasa Sabaliauskaite2, 3 & Albertas Dauksa5


1Lithuanian University of Health Sciences, Institute of Endocrinology, Kaunas, Lithuania; 2National Cancer Institute, Laboratory of Genetic Diagnostic, Vilnius, Lithuania; 3Vilnius University Life Sciences Centre, Institute of Biosciences, Vilnius, Lithuania; 4Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Department of Endocrinology, Kaunas, Lithuania; 5Lithuanian University of Health Sciences, Institute of Digestive Research, Kaunas, Lithuania


Introduction: Papillary thyroid carcinoma (PTC) is the most common type of differentiated thyroid cancer, accounting for about 80% of all cases of thyroid cancer. Generally, PTC is an indolent disease and shows a good prognosis in most patients. However, up to 30% of patients have local tumor renewal or systemic spread. It is crucial to identify patients with a high risk of disease progression. DNA methylation biomarkers may provide clinically valuable information and improve the early non-invasive prognosis of PTC.

Aim of the study: To evaluate DNA methylation level changes of selected genes in peripheral blood plasma samples in PTC patients before and 4-6 weeks after surgery.

Methods: The studyincluded 68 patients with a histologically confirmed diagnosis of PTC with different histological variants: classical (n= 29), diffuse sclerosing (n= 17), follicular (n= 18), and tall cell carcinoma (n= 4). Peripheral blood samples were collected before surgery and 4-6 weeks after surgery during 2020 – 2021 in Hospital of Lithuanian University of Health Sciences, Kaunas clinics. DNA methylation level changes of TSHR gene were analysed by quantitative methylation-sensitive polymerase chain reaction. DNA methylation levels of TSHR were compared before and one month after the surgery using both paired and non-paired non-parametrical tests.

Results: Significantly lower TSHR promoter methylation levels were found 4-6 weeks after surgery compared to samples collected before surgery (P=0.034) in follicular variant of PTC. Paired sample analysis showed a statistically higher TSHR methylation level before surgery compared to TSHR methylation level after surgery in follicular variant PTC (P=0.002).

Conclusion: TSHR promoter methylation level changes may be a promising biomarker in predicting PTC prognosis.

Funding: This study was supported by the Lithuanian Research Council (Grant No. S-SEN-20-14 “The role of epigenetic markers for early detection of papillary thyroid carcinoma and prognostic significance in long-term outcome in elderly patients”).

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.